Less than two months after the Food and Drug Administration approved the first-ever drug that uses a Nobel-winning technique to mute disease-causing genes, the pharmaceutical industry is already looking for a piece of the next one.
Within the last month, Eli Lilly, Alexion, and Janssen have all announced licensing and collaboration deals — each potentially worth billions — with companies developing treatments with the technique known as RNAi.
About the Author Reprints
There is no way in hell Alnylam’s patisiran will sell $1B . It’s in a highly competitive market with a narrow label and IV infusion every 3 weeks.
My Son is 8 years old end exone 49 50 deleted please help me